28 June 2022 - - US-based neuroscience company Inscopix, Inc has launched new multimodal behavioral technology called the nVision Platform, which allows for single-step synchronization between in vivo neural circuit imaging data from the company's miniscope-based platforms and animal behavior video recordings, the company said.

Additionally, the company has entered into a co-marketing agreement with behavioral research tools innovator Noldus Information Technology BV.

A new innovation for the real-time integration of behavior with miniscope imaging, the nVision Platform enables the simultaneous capture of behavior and calcium imaging movies in a single session.

Researchers will now be able to perform precise time correlations between brain and behavior activities, such as exploration or navigation and choice tasks.

Upon release, nVision would be the only integrated technology for the two methods during free behavior, providing scientists with unique, synchronized insights into brain health and disease.

Through the Noldus collaboration, researchers can add Noldus' pioneering EthoVision XT video tracking software to the nVision workflow.

By plugging in the behavior video into Noldus' user-friendly interface, the software is capable of tracking and analyzing the behavior, movement, and activity of the animal being studied.

The nVision Platform, along with other innovations around the company's miniature microscope-based brain mapping platforms, will be featured at the FENS Forum 2022 being held in Paris, France July 9-13.

The Inscopix FENS showcase will highlight key product and applications updates, including the flagship nVue System for dual-color imaging, neurotransmitter and blood flow imaging capabilities and the 2021-released cloud-based Inscopix Data Exploration, Analysis and Sharing (IDEAS) Platform.

Inscopix will provide details of abstracts throughout the meeting via Twitter at @inscopix.

Inscopix's technology is already in use by basic and translational researchers in both academia and pharma in more than 600 labs that have produced almost 200 publications describing many breakthrough discoveries about brain function and disorders.

By uncovering the connections between neurons, the company and its collaborators are able to gain insights into directly actionable targets for therapeutic intervention to treat brain-related diseases, the company said.